Hedge Funds Are Buying SciClone Pharmaceuticals, Inc. (SCLN)

Consequently, key money managers have been driving this bullishness. Millennium Management, led by Israel Englander, assembled the largest position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Millennium Management had $2.1 million invested in the company at the end of the quarter. Paul Marshall and Ian Wace’s Marshall Wace LLP also made a $1.7 million investment in the stock during the quarter. The other funds with new positions in the stock are Chao Ku’s Nine Chapters Capital Management, Louis Navellier’s Navellier & Associates, and Peter Algert and Kevin Coldiron’s Algert Coldiron Investors.

Let’s now take a look at hedge fund activity in other stocks similar to SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). We will take a look at Triangle Capital Corporation (NYSE:TCAP), United Financial Bancorp, Inc. (NASDAQ:UBNK), AeroVironment, Inc. (NASDAQ:AVAV), and Aceto Corporation (NASDAQ:ACET). All of these stocks’ market caps resemble SCLN’s market cap.

As you can see these stocks had an average of 8.75 hedge funds with bullish positions and the average amount invested in these stocks was $30 million. That figure was $65 million in SCLN’s case. United Financial Bancorp, Inc. (NASDAQ:UBNK) is the most popular stock in this table. On the other hand AeroVironment, Inc. (NASDAQ:AVAV) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Suggested Articles:
Countries With Free Healthcare
Easiest Second Languages To Learn
Highest Paying Countries For Software Engineers

Disclosure: None